Clinical Evaluation of a Recombinant Factor VIII Preparation (Kogenate) in Previously Untreated Patients with Hemophilia A
- 1 December 2003
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in International Journal of Hematology
- Vol. 78 (5), 467-474
- https://doi.org/10.1007/bf02983823
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Antibodies to Heterologous Proteins in Hemophilia A Patients Receiving Recombinant Factor VIII (Recombinate™)Thrombosis and Haemostasis, 2002
- Incidence of inhibitors in haemophilia A patients – a review of recent studies of recombinant and plasma‐derived factor VIII concentratesHaemophilia, 1999
- The incidence of factor VIII inhibitors in the United Kingdom, 1990‐93British Journal of Haematology, 1995
- A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group.1993
- Clinical Study of Recombinant Factor VIII (BL-160) in Hemophilia A PatientsJapanese Journal of Thrombosis and Hemostasis, 1993
- Viral safety and inhibitor development associated with monoclonal antibody-purified F VIII CAnnals of Hematology, 1991
- Human Recombinant DNA–Derived Antihemophilic Factor (Factor VIII) in the Treatment of Hemophilia ANew England Journal of Medicine, 1990
- The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors.1988
- Expression of active human factor VIII from recombinant DNA clonesNature, 1984
- Characterization of the human factor VIII geneNature, 1984